Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
Introduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and c...
Main Authors: | Anam A. Mazharuddin, Andrew T. Whyte, Dan S. Gombos, Nimisha Patel, Azadeh Razmandi, Amina L. Chaudhry, Nagham S. Al-Zubidi |
---|---|
Format: | Article |
Language: | English |
Published: |
Innovative Healthcare Institute
2022-11-01
|
Series: | Journal of Immunotherapy and Precision Oncology |
Subjects: | |
Online Access: | https://theijpt.org/doi/pdf/10.36401/JIPO-22-14 |
Similar Items
-
Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review
by: Shruthi Harish Bindiganavile, et al.
Published: (2021-02-01) -
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01) -
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
by: Lin Zhou, et al.
Published: (2021-08-01) -
Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
by: Karima Khimani, et al.
Published: (2022-03-01) -
Ocular Inflammation Post-Vaccination
by: Yaru Zou, et al.
Published: (2023-10-01)